^
Association details:
| Biomarker: | CD47 overexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | VT1021 (CD36 stimulant, TSP1 stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors
Published date:
11/09/2020
Excerpt:
Through all doses tested, VT1021 was safe and well tolerated, with dose proportional PK properties. In addition, VT1021 has demonstrated activities in reprogramming the TME which resulted in a high disease control rate in subjects with tumors expressing both high CD36 and high CD47.
DOI:
http://dx.doi.org/10.1136/jitc-2020-SITC2020.0374
